The data, published in the New England Journal of Medicine, show the drug shortened the course of illness from an average of 15 days to about 11 days
.
"However, given high mortality despite the use of remdesivir, it is clear that treatment with an antiviral drug alone is not likely to be sufficient," they added."Future strategies should evaluate antiviral agents in combination with other therapeutic approaches or combinations of antiviral agents to continue to improve patient outcomes in Covid-19."
"Even though the trial was ongoing, the data and safety monitoring board made the recommendation to unblind the results to the trial team members from the NIAID, who subsequently decided to make the results public," the researchers wrote. But some critics complained that the data were not published and worried the federal government was rushing the results.
"Serious adverse events occurred in 114 patients in the remdesivir group and 141 patients in the placebo group," the researchers wrote.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
What sports, fitness activities can be done in the time of COVID-19?
Read more »
Celebrities react to news about Philippines experiencing second wave of COVID-19 transmissionJanine Gutierrez, Aiai Delas Alas, Alessandra de Rossi, and other celebrities reacted to DOH Secretary Francisco Duque III's claim that the COVID-19 transmission in the Philippines is now on its second wave.
Read more »
Not flattening the curve yet: PH still on first wave of COVID-19 infections, expert saysThe Philippines has yet to move past the 'first wave' of COVID-19 cases, an infectious disease expert said as he contradicted claims that the country is now riding the second surge of infections.
Read more »
DOT: Tourism industry one of the hardest hit amid COVID-19 pandemic
Read more »